TVM Capital Life Science to participate in LSI USA ’23 Emerging Medtech Summit 2023

TVM Life Science Management GmbH

Enterprise highlights significant investments from its industrial-stage medtech portfolio

MONTREAL and MUNICH, Germany, March 17, 2023 (GLOBE NEWSWIRE) — TVM Capital Life Science (“TVM”), a leading international venture capital firm focused on investments in life sciences innovation, these days announced that Dr. Luc Marengère, Managing Companion, and Dr. Sascha Berger, Widespread Companion of TVM, will participate in the upcoming LSI USA ’23 Emerging Medtech Summit 2023, which brings with each and every other leading innovators, active investors and committed strategics from the medtech industry to companion and create subsequent-generation healthcare technologies. The conference will take place March 20-23, 2023, in Dana Point, California, USA.

“Medtech innovation plays a pivotal component in the healthcare ecosystem and has the potential to revolutionize the industry by enhancing patient outcomes, increasing efficiency, and minimizing charges. A single significant element of our method is to invest in disruptive, breakthrough, industrial-stage technologies that map essential future trends and drastically transform current standard-of-care. In addition to connecting with fellow investors and dealmakers to speak about marketplace possibilities and demands, we seem forward to meeting young, hugely revolutionary enterprises at the LSI Summit to more expand TVM’s highly effective medtech portfolio,” stated Dr. Luc Marengère.

TVM pursues a one particular of a type two-pronged method, investing in differentiated overall health-connected technologies with industrial proof-of-notion and late clinical-stage therapeutics as nicely as financing revolutionary early-stage therapeutics by way of a single asset firm tactic (Project-Focused Enterprise, PFC) that leverages TVM’s strategic connection with international pharmaceutical firm, Eli Lilly and Enterprise. With its late-stage medtech investments, the Enterprise focuses on revolutionary firms from North America or the EU functioning to transform overall health-connected practice with their groundbreaking devices and technologies.

Story continues

Dr. Sascha Berger added: “TVM’s track record of productive collaboration highlights our partnership and worth-constructing tactic with innovators. As appropriate partners, we function closely with our portfolio enterprises, striving to totally grasp their ideas, and find tactics to advance their innovations to accelerate improvement, facilitate marketplace expansion and at some point assistance them create into or continue to be a leader in their respective markets. With our current fund TVM Life Science Innovation II, we continue to expand our method, that has been validated by way of a quantity of enterprises in each and every Fund I and II, to create a portfolio of differentiated options with highly effective leadership teams.”

Investment highlights from TVM’s medtech industrial-stage portfolio involve:

• Access Vascular Inc. has produced and commercializes award-winning intravenous catheters addressing the most well-liked and pricey complications of intravenous therapy: infection, thrombosis, and phlebitis. Engineered to mimic the body’s organic chemistry, Access Vascular catheters are created to evade foreign physique response and connected complications.

• Egg Overall health-connected has produced and commercializes a lab radiation protection strategy that drastically reduces scatter radiation exposure by means of interventional angiographic procedures. During an X-ray, radiation reflects off a patient and scatters to any one particular else in the region. This outcomes in an enhanced threat of cancer chromosomal abnormalities, skin harm and eye injury for healthcare specialists in this field. EGGNEST™ reduces scatter radiation exposure by 91% for the total group without having obtaining interrupting the workflow.

• Emovi’s technologies and AI selections address clinical challenges that exist by way of the continuum of care for people with knee discomfort and pathology. The Enterprise has produced the only FDA cleared, Wellness Canada licensed and CE Marked overall health-connected device to assess the 3D motion of the knee and totally grasp what is taking spot in patient’s knee in order to far improved establish causes of symptoms and propose a productive care tactic.

• Kent Imaging, a leading innovator in close to-infrared tissue oxygenation imaging, develops, manufactures, and markets overall health-connected technologies that supports correct-time decision-making in wound care, vascular and surgical subspecialties and tracks the healing technique. Kent Imaging targets limb preservation and reconstructive surgical markets – regions with clear unmet have to have to have, as non-healing wounds are a major burden to people and the healthcare strategy.

• Panthera Dental, a globe leader in CAD/CAM implant selections and dental sleep appliances, has efficiently combined creativity, science and know-how to bring to marketplace its proprietary revolutionary technologies to give subsequent-generation options to the dental industry as nicely as a novel innovation to treat sleep apnea. The Enterprise just lately launched a new item: The Magnet-XTM, the world’s incredibly very first removable magnetic implant bar giving steady forces, lateral guidance and stability and uncomplicated handling for people with considerably much less dexterity.

About TVM Capital Life Science
TVM Capital Life Science (“TVM”) is a leading international venture capital firm focused on investing in life science innovations. The Enterprise has a hugely skilled transatlantic investment group and roughly $900 million beneath management. TVM’s portfolio focuses on therapeutics and overall health-connected technologies from North America and the EU that represent differentiated incredibly very first-in-class or excellent-in-class assets with the potential to transform standard of care.

TVM pursues a one particular of a type two-pronged method, financing revolutionary early-stage therapeutics by way of a single asset firm tactic (Project-Focused Enterprise, PFC) that leverages the firm’s strategic connection with international pharmaceutical firm, Eli Lilly and Enterprise. TVM also invests in differentiated industrial-stage overall health-connected technologies and late clinical-stage therapeutics.

With its late-stage investments, TVM focuses on differentiated overall health-connected technologies with industrial proof-of-notion as nicely as late-stage therapeutics anticipated to promptly attain major improvement or regulatory milestones. This method has been validated by way of a quantity of enterprises in each and every Fund I and II and the Colucid Pharmaceuticals exit.

The TVM investment group has worked with each and every other for extra than a decade to effectively make use of this revolutionary tactic to maximize returns for investors and finance new therapies and technologies to meaningfully increase patient lives.

Media Relations

MC Options AG

Europe: Anne Hennecke
Tel: +49 211 529 252 22
North America: Laurie Doyle
Tel: +1 339 832 0752
E mail: tvm@mc-options.eu